MoA-Based Potency Bioassays for Immunotherapy Programs Targeting the TIGIT/CD112R/CD226 Axis

Part # PS423


Here we show a portfolio of MOA-based bioassays for the TIGIT/CD112R/CD226 axis that can be used for antibody screening, characterization, potency and stability studies. These bioassays provide the following:

  • Biologically relevant measurement of antibody MOA
  • Consistent and reliable thaw-and-use format
  • Easy implementation, rapid results

Printed in USA.